What researchers study
Semaglutide is a GLP-1 receptor agonist. FDA-approved semaglutide prescription products are used for specific metabolic and cardiovascular indications under medical supervision.
Important: Clinical evidence for an FDA-approved or clinical-trial drug does not establish that an online research product with the same ingredient name is equivalent.
Potential side effects & unknowns
Approved semaglutide labeling identifies gastrointestinal adverse effects and important risks including pancreatitis, gallbladder disease, hypoglycemia in certain settings, kidney injury from volume depletion and other warnings. FDA has separately warned about dosing errors and adverse events with unapproved compounded products.
Evidence snapshot
Semaglutide has extensive randomized human clinical-trial evidence in regulated prescription products. That evidence does not verify the quality or equivalence of research products sold online under the same ingredient name.